Nasal Drug Delivery

SNBL’s nasal drug delivery platform is a proprietary system consisting of powder carrier technology and delivery device technology.

Expertise in Nasal Delivery

3D Nasal Cast Model

preview
next
June 19, 2018
SNBL will be exhibiting a booth showcasing our proprietary nasal delivery technology, feasibility study program, and the application of Nose-to-Brain technology at the World Congress of Basic and Clinical Pharmacology in Kyoto (WCP2018) – July 02-05, 2018. Location: Kyoto International Conference Center Kyoto (ICC Kyoto, Takaragaike, Sakyo-ku, Kyoto 606-0001, Japan)
June 15, 2018
SNBL will present new data for our proprietary nasal delivery technology as applied to Nose-to-Brain and systemic delivery. The following posters will be presented at the Controlled Release Society (CRS) Annual Meeting in New York, NY – July 22-24, 2018: In Vitro/in Vivo Evaluations Of Nose-to-Brain Drug Delivery Platform Technology In Monkeys (Yusuke Torikai, poster number: 574) Pharmacokinetic Analysis of Absorption Characteristics of a Novel Nasal Zolmitriptan Powder Formulation in Monkeys...
April 02, 2018
Shin Nippon Biomedical Laboratories (SNBL) launches a redesigned website for their nasal delivery system as part of the Translational Research (TR) Division. The new URL for the TR website has been changed. If you have already bookmarked our website, please change your bookmark to the new address below: Old: http://www.snbl-nds.co.jp/en/ New: http://www.snbl-nds.com/ The key points of the redesigned site are as follows: 1) Updated information for novel technology application based on...
December 19, 2016
Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"; CEO: Ryoichi Nagata; Tokyo, Japan) announces that third-party allocation of new shares have been concluded for Satsuma Pharmaceuticals, Inc. ("Satsuma"; President & CEO: John Kollins; California), which was established in the US to develop migraine therapeutics. The $12M financing was co-led by RA Capital Management, LLC ("RA Capital") and TPG Biotechnology Partners V, L.P. ("TPG"). Satsuma was established in June 2016, with the purpose to...
June 08, 2015
We are pleased to announce that official homepage of TR Company of SNBL, Ltd. was renewed. Our nasal delivery platform technology is widely applicable to small molecules, peptides and vaccines. The renewed homepage has been updated with information assessing the applicability of nasal delivery platform technology to potential compounds. We look forward to receiving your inquiry.
June 05, 2015
BIO One-on-One Partnering at the 2015 BIO International Convention is the largest venue for private company-to-company meeting in the world. In order to create new business opportunities utilizing SNBL's nasal platform technology, we look forward to meeting you at the BIO one-on-one meeting. Meeting request at BIO One-on-One Partnering: https://app.partnering.bio.org/BIO2015
March 03, 2015
Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"; CEO: Ryoichi Nagata; Tokyo, Japan) announces that an agreement has been concluded with ISA Pharmaceuticals through its fully-owned subsidiary ISA Therapeutics B.V.1) ("ISA"; CEO: Ronald Loggers; Leiden, Netherlands) on March 3, 2015. Under the agreement, SNBL will be evaluating its novel nasal vaccine delivery platform1) for prophylactic use of ISA's proprietary Synthetic Long Peptide (SLP®) immunotherapeutic, ISA1012). SNBL has succeeded in...
December 24, 2014
Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"; President: Ryoichi Nagata; Tokyo, Japan) announces the termination of a licensing agreement signed in April, 2013, with Besins Healthcare (CEO, Leslie Grunfeld; Belgium) regarding a nasal progesterone product. The agreement granted a license to use SNBL's novel nasal delivery technology platform for a nasal progesterone powder formulation, which was being developed by BHR Pharma, LLC (Virginia, USA; "BHR Pharma"), a 100% subsidiary company of...
October 16, 2014
In conjunction with Camargo Pharmaceutical Services, leaders in the area of 505(b)(2) development programs, SNBL will present our experience of two programs using SNBL's μco™ System, which obtained the FDA's acceptance for approval without Phase 3 clinical efficacy studies. For more information, click here.
August 13, 2014
Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"; CEO: Ryoichi Nagata; Tokyo, Japan) announces in conjunction with Sosei Group Corporation ("Sosei"; CEO: Shinichi Tamura; Tokyo, Japan) that a Letter of Intent has been executed to negotiate terms of joint development for multiple pharmaceutical products utilizing SNBL's nasal delivery technology platform1). As part of the Translational Research Business2), SNBL develops novel pharmaceutical products based on its novel nasal delivery technology...

Show more